Author

David Langan

Observed names: David P. Langan, David P Langan, David P. Langan, Langan, David

Observed institutions: University of Maryland, Baltimore, Veterans Health Administration, United States Army Medical Research Institute of Infectious Diseases, NexImmune (United States), Baltimore VA Medical Center, Deka Biosciences (United States)

ORCID: 0000-0002-4525-9767

Observed ORCID: 0000-0002-4525-9767

OpenAlex ID: A5083322430

Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome

2018 · Steven Dudics, David Langan, et al. · International Journal of Molecular Sciences · 165

PDF

Microbiota-Derived Metabolites, Indole-3-aldehyde and Indole-3-acetic Acid, Differentially Modulate Innate Cytokines and Stromal Remodeling Processes Associated with Autoimmune Arthritis

2021 · David Langan, Darren J. Perkins, et al. · International Journal of Molecular Sciences · 71

PDF

siRNA Screen Identifies Trafficking Host Factors that Modulate Alphavirus Infection

2016 · Sheli R. Radoshitzky, Gianluca Pegoraro, et al. · PLoS Pathogens · 39

PDF

Common innate pathways to autoimmune disease

2020 · David Langan, Noel R. Rose, et al. · Clinical Immunology · 31

T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection

2017 · Christopher L Cooper, Karen A Martins, et al. · Emerging Microbes & Infections · 14

Modulation of autoimmune arthritis by environmental ‘hygiene’ and commensal microbiota

2018 · David Langan, Eugene Y. Kim, et al. · Cellular Immunology · 11

Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity

2025 · Julie J. Ahn, Steven Dudics, et al. · Cell Reports Medicine · 10

PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy

2026 · Hong Lou, David Langan, et al. · Neoplasia · 5

AIM™ platform: A new immunotherapy approach for viral diseases

2022 · David Langan, Ruipeng Wang, et al. · Frontiers in Medicine · 3

PDF

97 High throughput screening of HPV-antigen peptides and expansion of tumor-specific T cells for adoptive cell therapy of HPV-associated malignancies

2021 · David Langan, Jourdain Lemaster, et al. · Journal for ImmunoTherapy of Cancer · 3

PDF

Targeted therapy to treat cervical cancer: Alpelisib, Inavolisib and Capivasertib, PI3-kinase and AKT inhibitors, suppresses PIK3CA mutated cervical cells and potentiate immunotherapy

2026 · Sharon Wu, Michael Dean, et al. · Gynecologic Oncology

Abstract 3747: Long-read whole genome sequencing identifies genes for targeted therapy to treat cervical cancer

2025 · Michael C. Dean, Sonam Tulsyan, et al. · Cancer Research

Designing the Optimal Artificial Immune Synapse: Combining TCEs with Diakines TM (Coupled and Tumor Surface Targeted Cytokines)

2025 · Jacob C. McCright, David P. Langan, et al. · SSRN Electronic Journal

951 Balanced Diakine™ targeted cytokines localize within the immunological synapse and augment immune response in combination with T cell engagers

2024 · Jacob McCright, Steven Dudics, et al. · Journal for ImmunoTherapy of Cancer

43 Immune biomarkers from phase 1 first-in-human trial treating advanced cancer patients with DK210(EGFR) compared to ex vivo DiakineTM response assay

2024 · Abdul Rafeh Naqash, Adanma Ayanambakkam, et al. · Journal for ImmunoTherapy of Cancer

353 Artificial immune modulation adoptive cell therapies for virally driven malignancies

2022 · David Langan, Keshanti Tidwell, et al. · Journal for ImmunoTherapy of Cancer

PDF

EBOV Protection Is Supported by T Cell-Dependent Humoral Responses But Is Not Requisite for Survival

2016 · Christopher L. Cooper, Karen Martins, et al.

Works count: 19

Citation count: 352

H-index: 7

I10-index: 7